Review
Copyright ©2014 Baishideng Publishing Group Inc.
World J Med Genet. May 27, 2014; 4(2): 19-26
Published online May 27, 2014. doi: 10.5496/wjmg.v4.i2.19
Table 1 Prevalence of hepatitis B surface antigen in the general Asian population
CountryHBsAg positivity (%)Ref.
Southeast Asia
Brunei4.7Sebastian et al[30]
6.0Alexander et al[31]
Cambodia7.7OI et al[14]
10.8Sa-Nguanmoo et al[10]
Indonesia3.5-9.1Hasan[11]
4.9Achwan et al[12]
2.1-10.5Lusida et al[13]
Laos6.9Jutavijittum et al[24]
8.7Sa-Nguanmoo et al[10]
Malaysia3.0-5.0Merican et al[22]
0.5-1.8Yousuf et al[23]
Myanmar9.7Sa-Nguanmoo et al[10]
Philippines10.0Lingao et al[17]
2.0-16.0Lansang et al[18]
16.7Wong et al[19]
Singapore3.6-4.0James et al[28]
2.7-4.0Ang et al[29]
Thailand4.0Suwannakarn et al[15]
13.8Louisirirotchanakul et al[16]
Vietnam11.4Viet et al[20]
7.5Reekie et al[21]
East Asia
China2.4Ting-Lu et al[25]
1.0Liu et al[26]
10.6Chen et al[27]
Japan0.8Merican et al[22]
South Korea3.0-4.0, 6.0Kim et al[32]
6.0Hyun et al[33]
Table 2 Summary of nucleos(t)ide analogues
LamivudineAdefovirEntecavirTelbivudineTenofovirRef.
Analogue typeNucleosideNucleotideNucleosideNucleosideNucleotide
Introduction (yr)19992002200520062008
Product name (company)Zefix (GSK)Hepsera (Gilead)Baraclude (BMS)Sebivo (Novartis)Viread (Gilead)
Dose100 mg10 mg0.5 mg600 mg300 mg
Once dailyOnce dailyOnce dailyOnce dailyOnce daily
AdvantageLow costEffective for HIV coinfectionPossible for pregnancyEffective for HIV coinfection[89]
DisadvantageHigh rate of drug resistanceRenal dysfunction Fanconi anemiaNot recommend for pregnancyRenal dysfunctionRenal dysfunction Fanconi anemia
Undetectable HBV-DNA
HBeAg positive36%21%67%60%76%[90]
HBeAg negative89%72%90%88%93%
HBeAg seroconversion22%12%21%23%21%[91]
Drug-resistance24%0%0.2%4%0%[92]
Drug-resistant mutationV173l, L180M, A181T, M204V/IA181V/T, N236TI169T, L180M, T184A/F/L/S, S202G/I, M204V, M250VM204V/IA181V/T, N236T